Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 10:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 55 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Metaiodobenzylguanidine (MIBG) Clear all
Active, not recruiting Phase 2 Interventional Results available

Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)

NCT04385277
View directory record Official record
Conditions
Ganglioneuroblastoma, Nodular, Neuroblastoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Dinutuximab, FDG-Positron Emission Tomography, Iobenguane I-123, Irinotecan, Isotretinoin, Magnetic Resonance Imaging, Multigated Acquisition Scan, Sargramostim, Temozolomide
Procedure · Biological · Radiation + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
70
States / cities
Mesa, Arizona • Little Rock, Arkansas • Downey, California + 58 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 3, 2026, 10:56 AM EDT
Completed Phase 3 Interventional

High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors

NCT00037869
View directory record Official record
Conditions
Neuroendocrine Tumors, Metastases, Neoplasm
Interventions
I-131 Metaiodobenzylguanidine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
2 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Oct 3, 2026, 10:56 AM EDT
Available No phase listed Expanded access

Expanded Access Protocol Using 131I-MIBG

NCT01590680
View directory record Official record
Conditions
Neuroblastoma, Pheochromocytoma, Paraganglioma
Interventions
I-131 MIBG
Radiation
Lead sponsor
Jubilant DraxImage Inc.
Industry
Eligibility
12 Months and older
U.S. locations
19
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 3, 2026, 10:56 AM EDT
Completed Phase 2 Interventional

131 I-MIBG in Treating Patients With Refractory or Relapsed Neuroblastoma

NCT00293319
View directory record Official record
Conditions
Neuroblastoma
Interventions
filgrastim, iobenguane I 131
Biological · Radiation
Lead sponsor
University of California, San Francisco
Other
Eligibility
1 Year and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
3
States / cities
San Francisco, California • Ann Arbor, Michigan • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 18, 2014 · Synced Oct 3, 2026, 10:56 AM EDT
Completed Phase 1 Interventional Results available

Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin

NCT01175356
View directory record Official record
Conditions
Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Interventions
3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Cisplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide Phosphate, External Beam Radiation Therapy, In Vitro-Treated Peripheral Blood Stem Cell Transplantation, Intensity-Modulated Radiation Therapy, Iobenguane I-131, Isotretinoin, Laboratory Biomarker Analysis, Melphalan, Pharmacological Study, Questionnaire Administration, Therapeutic Conventional Surgery, Topotecan Hydrochloride, Vincristine Sulfate
Radiation · Procedure · Drug + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 30 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 3, 2026, 10:56 AM EDT
Terminated Phase 1 Interventional

Cardiac Resynchronization and Iodine Meta-Iodobenzylguanidine (MIBG) Imaging

NCT01522378
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
123 iodine metaiodobenzylguanidine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 3, 2026, 10:56 AM EDT
Not yet recruiting Phase 2 Interventional

NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab

NCT07261241
View directory record Official record
Conditions
Neuroblastoma
Interventions
Radiation: 131I-MIBG, Dinutuximab, Vorinostat
Drug
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
1 Year to 30 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 3, 2026, 10:56 AM EDT
No Longer Available No phase listed Expanded access

131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma

NCT03649438
View directory record Official record
Conditions
Relapsed Neuroblastoma, Metastatic Pheochromocytoma
Interventions
131 I-Metaiodobenzylguanidine, Potassium Iodide, G-csf
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 3, 2026, 10:56 AM EDT
Completed Phase 2 Interventional

131MIBG to Treat Malignant Pheochromocytoma

NCT00028106
View directory record Official record
Conditions
Pheochromocytoma
Interventions
[131]I-MIBG, 6-[18F]Fluorodopamine, [123]I-MIBG
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 3, 2026, 10:56 AM EDT
Completed Phase 4 Interventional Results available

Open-label, Test-retest Study Assessing Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView.

NCT01936649
View directory record Official record
Conditions
Heart Failure (HF), Ventricular Dysfunction, Left
Interventions
AdreView (Iobenguane I 123 Injection)
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 8, 2016 · Synced Oct 3, 2026, 10:56 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Meta-Iodobenzylguanidine Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease

NCT00126425
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
123I-mIBG (meta-iodobenzylguanidine)
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
587 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Oct 3, 2026, 10:56 AM EDT
Completed Not applicable Interventional Results available

Pathogenesis of Stress-Induced Cardiomyopathy by I-123 MIBG

NCT01432626
View directory record Official record
Conditions
Stress Induced Cardiomyopathy
Interventions
I-123 radiolabeled metaiodobenzylguanidine cardiac imaging
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 22, 2016 · Synced Oct 3, 2026, 10:56 AM EDT
Approved For Marketing No phase listed Expanded access

Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma

NCT01377532
View directory record Official record
Conditions
Pheochromocytoma, Paraganglioma
Interventions
131 I-Metaiodobenzylguanidine (131 I-MIBG)
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
2 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Oct 3, 2026, 10:56 AM EDT
Recruiting Phase 2 Interventional

Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

NCT00107289
View directory record Official record
Conditions
Neuroblastoma, Pheochromocytoma
Interventions
iobenguane I 131
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
1 Year and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 3, 2026, 10:56 AM EDT
Completed Phase 1 Interventional

N2000-01: Double Infusion of Iodine I 131 Metaiodobenzylguanidine Followed by Autologous Stem Cell Transplantation

NCT00083135
View directory record Official record
Conditions
Neuroblastoma
Interventions
filgrastim, autologous bone marrow transplantation, peripheral blood stem cell transplantation, iobenguane I 131
Biological · Procedure · Radiation
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
1 Year to 30 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 3, 2026, 10:56 AM EDT
Withdrawn Phase 2 Interventional

Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma

NCT00992173
View directory record Official record
Conditions
Neuroblastoma
Interventions
Ultratrace Iobenguane I 131
Drug
Lead sponsor
Molecular Insight Pharmaceuticals, Inc.
Industry
Eligibility
12 Months and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
20
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2015 · Synced Oct 3, 2026, 10:56 AM EDT
Completed Phase 2 Interventional Results available

131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat

NCT02035137
View directory record Official record
Conditions
Neuroblastoma
Interventions
131I-MIBG, Vincristine, Irinotecan, Vorinostat
Radiation · Drug
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
2 Years to 30 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
13
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Oct 3, 2026, 10:56 AM EDT
Active, not recruiting Phase 2 Interventional

MIBG Therapy for Patients With MIBG Avid Tumors

NCT02378428
View directory record Official record
Conditions
MIBG Avid Tumors
Interventions
MIBG
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
12 Months to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 3, 2026, 10:56 AM EDT
Completed Not applicable Interventional

MIBG for Refractory Neuroblastoma and Pheochromocytoma

NCT01850888
View directory record Official record
Conditions
Relapsed Neuroblastoma, Metastatic Pheochromocytoma
Interventions
131 I-Metaiodobenzylguanidine (131I-MIBG), Potassium iodide solution, G-CSF, hematopoietic stem cell infusion
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
1 Year and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 3, 2026, 10:56 AM EDT
Completed Phase 2 Interventional Results available

Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

NCT00831844
View directory record Official record
Conditions
Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Childhood Hepatoblastoma, Childhood Synovial Sarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Adrenocortical Carcinoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Liver Cancer, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive, Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Retinoblastoma, Recurrent Wilms Tumor and Other Childhood Kidney Tumors
Interventions
cixutumumab, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
7 Months to 30 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
93
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 78 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Oct 3, 2026, 10:56 AM EDT
Completed Phase 1 Interventional

N99-01: Combination Chemotherapy, Radiation Therapy, and Stem Cell Transplantation in Treating Patients With Neuroblastoma

NCT00005978
View directory record Official record
Conditions
Neuroblastoma
Interventions
filgrastim, carboplatin, etoposide, melphalan, autologous bone marrow transplantation, peripheral blood stem cell transplantation, iobenguane I 131, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
1 Year to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
15
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2010 · Synced Oct 3, 2026, 10:56 AM EDT
Completed Phase 1 Interventional Results available

MIBG With Dinutuximab +/- Vorinostat

NCT03332667
View directory record Official record
Conditions
Neuroblastoma
Interventions
131I-MIBG, Dinutuximab, Vorinostat, Sargramostim, Potassium Iodide
Radiation · Drug
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
1 Year to 30 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Oct 3, 2026, 10:56 AM EDT
No Longer Available No phase listed Expanded access

Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma

NCT01838187
View directory record Official record
Conditions
Neuroblastoma, Pheochromocytoma, Paraganglioma
Interventions
I-131 MIBG, Vorinostat
Radiation · Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Months and older
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Oct 3, 2026, 10:56 AM EDT